Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation
Source abstract
Abstract
Effective delivery of drugs to alveoli in a controlled manner using hydrophobic polymers as carriers has already been reported. Preclinical studies revealed that toxicity and hydrophobicity are related to each other in pulmonary delivery. Here, we are reporting a chemically modified dextran having amphiphilicity and cationicity achieved by controlled grafting of stearyl amine. Two proportions of lipopolymers were synthesized and physico-chemical characterization was carried out. In vivo evaluation of sub-acute toxicity of the synthesized lipopolymer in Sprague-Dawley rats was carried out for three months. This was followed by a histological evaluation of the sacrificed animal's lung. Further, the synthesized lipopolymer was formulated with drug (Rifampicin) loaded inhalable microparticles through spray drying. The final drug formulation was tested for toxicity and proinflammatory responses in human cell lines. Dose deposition efficiency of the formulation was determined using Anderson Cascade Impactor.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Inhalation therapy: an historical review10.3132/pcrj.2007.00017 ↗
2. Inhaling medicines: delivering drugs to the body through the lungs10.1038/nrd2153 ↗
3. Formulation strategy and use of excipients in pulmonary drug delivery10.1016/j.ijpharm.2010.03.017 ↗
4. Dry powder inhalers for optimal drug delivery10.1517/14712598.4.1.23 ↗
5. Evolution of dry powder inhaler design, formulation, and performance10.1053/rmed.2001.1276 ↗
6. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems10.1007/s11095-006-9218-8 ↗
7. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization10.1023/A:1007527204887 ↗
8. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants10.1016/j.ijpharm.2010.11.021 ↗
9. Inhalable microparticles containing large payload of anti-tuberculosis drugs10.1016/j.ejps.2007.06.006 ↗
10. In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration10.1016/0168-3659(92)90101-V ↗
11. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery10.1007/s11095-009-9894-2 ↗
12. Trojan particles: large porous carriers of nanoparticles for drug delivery10.1073/pnas.182233999 ↗
13. The Gibbs equation versus the Kelvin and the Gibbs-Thomson equations to describe nucleation and equilibrium of nano-materials10.1166/jnn.2012.5774 ↗
14. Nanosuspensions in drug delivery10.1038/nrd1494 ↗
15. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates10.1016/j.colsurfa.2010.01.066 ↗
16. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗
17. Synthesis and characterization of cationic micelles self-assembled from a biodegradable copolymer for gene delivery10.1021/bm061051c ↗
18. Self-assembling micelle-like nanoparticles based on phospholipid–polyethyleneimine conjugates for systemic gene delivery10.1016/j.jconrel.2008.09.079 ↗
19. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly (amidoamine) for siRNA delivery10.1016/j.biomaterials.2013.03.056 ↗
20. The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin10.1016/j.biomaterials.2014.02.010 ↗
21. Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery10.1021/nn100927t ↗
22. Spray-dried microparticles containing polymeric micelles encapsulating hematoporphyrin10.1208/s12248-009-9172-6 ↗
23. Surface grafted chitosan gels. Part I. Molecular insight into the formation of chitosan and poly (acrylic acid) multilayers10.1021/la5013186 ↗
24. A pilot study to compare tobramycin 80mg injectable preparation with 300mg solution for inhalation in cystic fibrosis patients
25. Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10
26. Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity10.1016/j.ijpharm.2013.04.009 ↗
27. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery10.1021/mp2003785 ↗
28. Respirable nanocarriers as a promising strategy for antitubercular drug delivery10.1016/j.jconrel.2014.05.038 ↗
29. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin10.1016/j.ijpharm.2003.11.031 ↗
30. Avascularity of tuberculous lesions: a major problem in therapy
31. C.-Y. Lai, D.R. Radu, Degradable crosslinked aminated dextran microspheres and methods of use, US 20110033548 A1, 2010.
32. Fabrication of porous polymer particles with high anion exchange capacity by amination reaction in aqueous medium10.1039/b514262h ↗
33. Histological examination of PLGA nanospheres for intratracheal drug administration10.1016/j.ijpharm.2007.12.041 ↗
34. Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation10.1016/j.jconrel.2009.12.016 ↗
35. Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury10.1152/ajplung.00477.2004 ↗
36. Acute and subacute pulmonary toxicity of low dose of ultrafine colloidal silica particles in mice after intratracheal instillation10.1080/01926230601094552 ↗
37. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles10.1016/j.nano.2007.03.003 ↗
38. Melting and crystallization behaviors of biodegradable polymers enzymatically coalesced from their cyclodextrin inclusion complexes10.1021/bm034078u ↗
39. Rheology of gastric mucin exhibits a pH-dependent sol–gel transition10.1021/bm0609691 ↗
40. Liquid and semisolid SLN™ dispersions for topical application: rheological characterization10.1016/j.ejpb.2004.04.009 ↗
41. Synthesis and rheological behavior of new hydrophobically modified hydrogels with tunable properties10.1021/ma061361n ↗
42. Fast ion conduction in layer-by-layer polymer films10.1021/cm020945a ↗
43. Intratracheal inhalation vs intratracheal instillation: differences in particle effects10.1093/toxsci/40.2.220 ↗
44. Lipopolysaccharide-induced acute lung injury in rats: comparative assessment of intratracheal instillation and aerosol inhalation10.1016/j.tox.2012.12.020 ↗
45. Kumar · 2010
46. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility10.1016/j.jconrel.2014.03.022 ↗
47. In vivo lung deposition and sub-acute inhalation toxicity studies of nano-sized alendronate sodium as an antidote for inhaled toxic substances in Sprague Dawley rats10.1016/j.etap.2013.05.016 ↗
48. Significance of active ion transport in transalveolar water absorption: a study on isolated rat lung10.1113/jphysiol.1987.sp016456 ↗
49. Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles10.1016/j.biomaterials.2004.04.006 ↗
50. The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate
51. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis10.4049/jimmunol.158.2.954 ↗
52. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini10.1073/pnas.98.3.1200 ↗
53. Methoxy poly (ethylene glycol) and ∊-caprolactone amphiphilic block copolymeric micelle containing indomethacin: II. Micelle formation and drug release behaviours10.1016/S0168-3659(97)00124-7 ↗
54. Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage
55. Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria10.1093/jac/48.1.7 ↗
56. Heat-stable dry powder oxytocin formulations for delivery by oral inhalation
57. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses10.1007/s11095-005-6155-x ↗
58. Force control and powder dispersibility of spray dried particles for inhalation10.1002/jps.21849 ↗